LONDON – 4basebio PLC (AIM: 4BB), a biotechnology company specializing in the production of synthetic DNA and nanoparticle delivery systems, announced that its CEO, Dr. Heikki Lanckriet, increased his stake in the company by purchasing additional shares. The transaction that took place on London Stock Exchange (LON:)’s AIM market involved the purchase of 12,000 ordinary shares at a price of 1,315 pence per share.

After this market purchase, Dr. Lanckriet’s total holdings in 4basebio now amount to 1,115,288 shares, representing 7.27% of the company’s issued share capital. The Company’s issued share capital consists of 15,477,395 common shares.

The CEO’s takeover is considered inside information under the EU Market Abuse Regulation, as amended by the United Kingdom (EU Exit) Market Abuse (Amendment) Regulation. This regulatory framework ensures transparency in financial transactions by corporate insiders and provides investors with important information about the actions of corporate executives.

4basebio’s focus is on the advancement of Advanced Therapy Medicinal Products (ATMPs) by providing high-quality synthetic DNA for research, therapeutic and pharmacological purposes, as well as the development of targeted non-viral vectors for efficient payload delivery to patients . The company’s goal is to become the market leader in its field.

The reporting of the transaction is carried out in accordance with Article 19(1) of Regulation (EU) No 596/2014, which requires public disclosure of transactions carried out by persons exercising managerial functions at an issuer.

Investors often monitor insider transactions because they can provide insight into executives’ confidence in the company’s prospects. The purchase of Dr. Lanckriet can be seen as a positive signal for the future of 4basebio.

This report is based on a press release from 4basebio PLC.

This article was created with the assistance of AI and reviewed by an editor. Further information can be found in our terms and conditions.